There is growing evidence that atrial fibrillation (AF) is prevalent in athletes and even in individuals participating in intense long term exercise at a non-competitive level. Several causes have been described for these phenomena including atrial remodeling, atrial fibrosis, inflammation, autonomic activation, body fluid changes and changes in blood volume and pressure. This article reviews the epidemiology, pathophysiological mechanisms and management options of AF in regards to exercise.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956135 | PMC |
| http://dx.doi.org/10.4022/jafib.1004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rationale and Design of the InsightPFA Trial: A Prospective, Multicenter, Randomized Controlled Trial of the Irreversible Electroporation-Based Pulsed Field Ablation Versus Radiofrequency Ablation in Chinese Patients With Symptomatic Paroxysmal Atrial Fibrillation.
J Cardiovasc Electrophysiol
January 2025
Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Background: Pulsed field ablation (PFA) is gaining recognition as a nonthermal, tissue-specific technique for the treatment of atrial fibrillation (AF). The preclinical evaluation of the investigated novel PFA system from Insight Medtech Co. Ltd has demonstrated feasibility, safety, and 30-day efficacy for pulmonary vein isolation (PVI) in the swine model.
View Article and Find Full Text PDFVery High-Power Short-Duration Ablation for Atrial Fibrillation in Adults With Congenital Heart Disease.
J Cardiovasc Electrophysiol
January 2025
Department of Electrophysiology, German Heart Center Munich, TUM University Hospital, Munich, Bavaria, Germany.
Introduction: Data regarding safety and long-term outcome of very high-power-short duration (vHPSD) ablation in adult congenital heart disease (ACHD) patients with paroxysmal or persistent atrial fibrillation (AF) are lacking.
Methods: Retrospective observational single-center study. The data of 66 consecutive ACHD patients (mean age 60 ± 12.
Population Pharmacokinetic Modelling of Apixaban in End-Stage Kidney Disease Patients with Atrial Fibrillation Receiving Haemodialysis.
Clin Pharmacokinet
January 2025
Laboratoire de Pharmacologie et Toxicologie, Department of Pharmacology, UR 3801, Reims University Hospital, University of Reims Champagne-Ardenne, 45 rue Cognacq Jay, 51092, Reims Cedex, France.
Background And Objective: Apixaban is increasingly being used for stroke prevention in patients with end-stage kidney disease with atrial fibrillation undergoing haemodialysis, but no pharmacostatistical model is available for dosage adjustment. This study aimed to develop a population pharmacokinetic model of apixaban in these patients to characterise its dialytic clearance and determine optimal dosing regimens and discontinuation timing before surgery.
Methods: Patients received 2.
Bridging the Gaps in Atrial Fibrillation Management in the Emergency Department.
J Cardiovasc Dev Dis
January 2025
Department of Cardiology, Jersey General Hospital, Gloucester Street, St. Helier, Jersey JE1 3QS, UK.
Atrial fibrillation (AF) frequently presents in emergency departments (EDs), contributing significantly to adverse cardiovascular outcomes. Despite established guidelines, ED management of AF often varies, revealing important gaps in care. This review addresses specific challenges in AF management for patients in the ED, including the nuances of rate versus rhythm control, the timing of anticoagulation initiation, and patient disposition.
View Article and Find Full Text PDFContemporary Trends in Pulsed Field Ablation for Cardiac Arrhythmias.
J Cardiovasc Dev Dis
December 2024
Department of Cardiology, Rush University Medical Center, Chicago, IL 60612, USA.
Pulsed field ablation (PFA) is a catheter-based procedure that utilizes short high voltage and short-duration electrical field pulses to induce tissue injury. The last decade has yielded significant scientific progress and quickened interest in PFA as an energy modality leading to the emergence of the clinical use of PFA technologies for the treatment of atrial fibrillation. It is generally agreed that more research is needed to improve our biophysical understanding of PFA for clinical cardiac applications as well as its potential as a potential alternative energy source to thermal ablation modalities for the treatment of other arrhythmias.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!